Listing of Claims:

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.

1. (Cancelled)

2. (Currently Amended) A compound of formula (I),



(I)

the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof, wherein

R^1 is C_{1-6}alkyl or thienyl;

R^2 is hydrogen or hydroxy or taken together with R^4 may form =O;

R^4 is hydrogen, C_{1-6}alkyl, furanyl, pyridinyl, arylC_{1-6}alkyl or  ;

n is 0 or 1;

X is N or CR^5, wherein R^5 is hydrogen;

R^3 is $-(CH_2)_s-NR^6R^7$ or is –Z-;

s is 0, 1 or 2;

R^6 is –CHO, C_{1-6}alkyl, piperidinylC_{1-6}alkyl, arylcarbonylpiperidinylC_{1-6}alkyl or arylC_{1-6}alkyl(C_{1-6}alkyl)aminoC_{1-6}alkyl;

R^7 is hydrogen or C_{1-6}alkyl;

~~R^8 is C_{1-6}alkyl;~~ when R^3 is–Z-, then Z is a heterocyclic ring system selected from (c-2) or (c-4);



(c-4) (c-2) (c-4)

and each R^{10} independently is hydrogen, C_{1-6}alkyl or C_{1-6}alkyloxyC_{1-6}alkylamino,

aryl is phenyl or phenyl substituted with halo, C_{1-6}alkyl or C_{1-6}alkyloxy;

with the proviso that when

n is 0, X is N, R^2 is hydrogen, R^3 is ~~a group of formula (b-1)~~Z, Z is the heterocyclic ring system (c-2) or (c-4) wherein said heterocyclic ring system Z is attached ~~to the rest of the molecule~~ with a nitrogen atom, and R^{10} is hydrogen; then

R^4 is other than ~~hydrogen,~~ C_{1-6}alkyl or pyridinyl.

3. (Currently Amended) A compound according to claim 2 ~~1~~ wherein

n is 0; X is N or CR^5, wherein R^5 is hydrogen; R^1 is C_{1-6}alkyl;

R^2 is hydrogen or hydroxy or taken together with R^4 may form =O; R^3 is -$(CH_2)_s$- NR^6R^7;

s is 0 or 1; R^6 is –CHO or C_{1-6}alkyl; and R^4 is hydrogen, C_{1-6}alkyl or  .

4. (Previously Presented) A compound selected from the group consisting of:

 compound 1	 compound 5
 compound 7	 compound 3
 compound 17	

and the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof.

5. (Cancelled)

6. (Currently Amended) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 2 ~~1~~.

7. -11. (Cancelled).

12. (Currently Amended) A combination of a compound with a chemotherapeutic agent wherein said compound is a compound of formula (I) according to Claim 2.

13. (Previously Presented) A process for preparing a compound as claimed in claim 2, comprising: a) hydrolysis of intermediates of formula (VIII),

(VIII) (I)

b) cyclization of intermediates of formula (X),



(X) (I-j)

or c) condensation of an ortho-benzenediamine of formula (XI) with an ester of formula (XII) wherein R^h is C_{1-6}alkyl, into compounds of formula (I), wherein X is N, herein referred to as compounds of formula (I-i),



(XI) (XII) (I-i)

14. (Cancelled)

15. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 3.

16. (Previously Presented)A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 4.

17. - 26. (Cancelled)

27. (Previously Presented) A combination of a compound with a chemotherapeutic agent wherein said compound is a compound of claim 3.

28. (Previously Presented) A combination of a compound with a chemotherapeutic agent wherein said compound is a compound of claim 4.

29. - 30. (Cancelled)

31. (New) A compound selected from


,

,

,

,

, or


and the *N*-oxide forms and the pharmaceutically acceptable addition salts thereof.

32. (New) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 31.

33. (New) A combination of a compound with a chemotherapeutic agent wherein said compound is a compound of claim 31.